Literature DB >> 10967037

Nuclear trafficking of photoreceptor protein crx: the targeting sequence and pathologic implications.

Y Fei1, T E Hughes.   

Abstract

PURPOSE: To identify the targeting sequence controlling the nuclear transport of the photoreceptor-specific transcription factor cone-rod homeobox (Crx) protein and to address the question of whether disease-causing Crx mutations disrupt the nuclear trafficking of the Crx protein.
METHODS: A series of cDNA fragments encoding Crx protein with deleted C termini were generated from mouse Crx cDNA by polymerase chain reaction (PCR). Point mutations were introduced into Crx coding sequence through PCR-based, site-directed mutagenesis. These mutated Crx fragments and the wild-type Crx were fused to cDNA encoding the jellyfish green fluorescent protein (GFP) and were transiently expressed in human embryonic kidney (HEK) 293T cells. Twelve to 48 hours after transfection, the living cells were counterstained with the red fluorescent nucleic acid dye SYTO 59 and examined with epifluorescence and confocal microscopy to determine the subcellular localization of Crx fusion proteins.
RESULTS: GFP expressed without a fusion partner was distributed evenly throughout the cells, whereas the wild-type Crx protein fused to GFP was localized only in the nucleus. GFP-tagged Crx proteins truncated at residues 107 or 165, demonstrated exclusive nuclear localization. In contrast, Crx fusion proteins truncated at residues 88, 79, 44, and 36, were located equally in both the cytoplasm and the nucleus. These results demonstrate that the nuclear localization signal (NLS) of Crx appears to reside in the amino acids between residue 88 and 107, which is surprising because the putative NLSs identified by prosite search are at residues 36 to 43 and 116 to 122. Further, a Crx fusion protein truncated at residue 99 was localized within the nucleus in the majority of the transfected cells, and two point mutations at residues 88 (K88T) and 98 (R98L) disrupted the nuclear localization, which indicates that the sequence between 88 and 98 in the C terminus of the Crx homeodomain contains a NLS that is essential for targeting Crx to the nucleus. However, the fusion protein truncated at residue 99 did not produce a complete nuclear localization in every transfected cell, suggesting that the Gln-rich domain at residues 99 to 106 is also required for the full accumulation of Crx protein in the nucleus. Two point mutations of Crx, R41W and E80A, that cause cone-rod dystrophy in humans and lie within the homeodomain but outside the NLS did not disrupt the nuclear localization of Crx protein, but a R90W mutation of Crx that causes human Leber congenital amaurosis (LCA) and resides within the NLS resulted in the fusion protein localized in both nuclei and cytoplasm in majority (51% to 69%) of the transfected cells.
CONCLUSIONS: The wild-type Crx protein is localized within the nucleus. The putative NLSs of Crx at residues 36 to 43 and 116 to 122 are not essential. The minimal NLS necessary for the nuclear transport of Crx protein is located at residues 88 to 98 in the C terminus of the homeodomain. The R90W mutation of Crx found in LCA disrupts the nuclear transport of the mutant protein. The defective nuclear trafficking of Crx protein may be a part of the molecular mechanism of this early-onset retinal degeneration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10967037

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

1.  OTEX, an androgen-regulated human member of the paired-like class of homeobox genes.

Authors:  Christoph Geserick; Bertram Weiss; Wolf-Dieter Schleuning; Bernard Haendler
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

Review 2.  On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention.

Authors:  G Jane Farrar; Paul F Kenna; Peter Humphries
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

3.  Molecular dissection reveals decreased activity and not dominant negative effect in human OTX2 mutants.

Authors:  Gilles Chatelain; Nicolas Fossat; Gilbert Brun; Thomas Lamonerie
Journal:  J Mol Med (Berl)       Date:  2006-04-11       Impact factor: 4.599

Review 4.  Nanoparticle-based technologies for retinal gene therapy.

Authors:  Jeffrey Adijanto; Muna I Naash
Journal:  Eur J Pharm Biopharm       Date:  2015-01-12       Impact factor: 5.571

5.  Two novel CRX mutant proteins causing autosomal dominant Leber congenital amaurosis interact differently with NRL.

Authors:  Lorenzo L Nichols; Ramakrishna P Alur; Elangovan Boobalan; Yuri V Sergeev; Rafael C Caruso; Edwin M Stone; Anand Swaroop; Mary A Johnson; Brian P Brooks
Journal:  Hum Mutat       Date:  2010-06       Impact factor: 4.878

6.  Mutation discovered in a feline model of human congenital retinal blinding disease.

Authors:  Marilyn Menotti-Raymond; Koren Holland Deckman; Victor David; Jaimie Myrkalo; Stephen J O'Brien; Kristina Narfström
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-06       Impact factor: 4.799

7.  Paired-type homeodomain transcription factors are imported into the nucleus by karyopherin 13.

Authors:  Jonathan E Ploski; Monee K Shamsher; Aurelian Radu
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 8.  Mechanisms of blindness: animal models provide insight into distinct CRX-associated retinopathies.

Authors:  Nicholas M Tran; Shiming Chen
Journal:  Dev Dyn       Date:  2014-06-27       Impact factor: 3.780

9.  Comparison of the transcription profile of simian parvovirus with that of the human erythrovirus B19 reveals a number of unique features.

Authors:  Zhengwen Liu; Jianming Qiu; Fang Cheng; Yonglie Chu; Yuko Yoto; M Gerard O'Sullivan; Kevin E Brown; David J Pintel
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  A specific box switches the cell fate determining activity of XOTX2 and XOTX5b in the Xenopus retina.

Authors:  Marco Onorati; Federico Cremisi; Yang Liu; Rong-Qiao He; Giuseppina Barsacchi; Robert Vignali
Journal:  Neural Dev       Date:  2007-06-27       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.